Triptorelin vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
TriptorelinAnti-Aging & Longevity
FOXO4-DRI- Summary
- Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with 100x the potency of native GnRH. An FDA-approved drug (Trelstar) for prostate cancer and precocious puberty, it is also used in post-cycle therapy (PCT) to rapidly restart the hypothalamic-pituitary-gonadal (HPG) axis after anabolic steroid suppression.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- Depot forms: weeks to months; aqueous: 6-8 hours
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- SubQ, IM
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 100 mcg
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Single injection
- 3 consecutive days per cycle
- Key Benefits
- Rapid HPG axis restart after steroid use
- Single-injection PCT protocol possible
- Massively elevates LH and FSH via flare effect
- Restores endogenous testosterone faster than traditional PCT
- FDA-approved for established medical uses
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Initial testosterone flare (intended)
- Injection site reactions
- Hot flashes (with chronic use)
- Decreased libido (chronic dosing)
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —